DCAI Dialysis of America (MM)

Levi & Korsinsky is investigating the Board of Directors of Dialysis Corp. of America (“DCAI” or the “Company”) (NasdaqGM: DCAI) for possible breaches of fiduciary duty and other violations of state law in connection with their attempt to sell the Company to U.S. Renal Care, Inc. (“USRC”). Under the terms of the transaction, DCAI shareholders will receive $11.25 in cash for each DCAI share of common stock they own for a total transaction value of approximately $112 million.

The investigation concerns whether the DCAI Board of Directors breached their fiduciary duties to DCAI stockholders by failing to adequately shop the Company before entering into this transaction and whether USRC is underpaying for DCAI shares, thus unlawfully harming DCAI stockholders. In particular, the Company recently announced a 14% increase in operating revenues and a 9% increase in operating income in 2009 as compared 2008. In addition, directors and executive officers of DCAI holding approximately 23% of DCA’s outstanding common stock have entered into agreements to tender their shares.

If you own common stock in DCAI and wish to obtain additional information, please contact us at the number listed below or visit http://www.zlk.com/dialysis-corp-america-dcai.html.

Levi & Korsinsky has expertise in prosecuting investor securities litigation and extensive experience in actions involving financial fraud and represents investors throughout the nation, concentrating its practice in securities and shareholder litigation.

Dialysis OF America (NASDAQ:DCAI)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024

Dialysis OF America (NASDAQ:DCAI)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024